IOVA

Iovance Biotherapeutics (IOVA)

About Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Details

Daily high

$4.21

Daily low

$3.80

Price at open

$4.20

52 Week High

$5.63

52 Week Low

$1.64

Market cap

1.6B

Dividend yield

0.00%

Volume

19.4M

Avg. volume

22.9M

P/E ratio

-3.53

Iovance Biotherapeutics News